Eli Lilly stock has ripped higher this year-and its earnings report could pump it up even more, Jacob Sonenshine writes in this week’s edition of Barron’s. Lilly’s obesity drugs are front and center this quarter. And if sales of those drugs do drive a solid earnings report, the stock should gain despite worries about valuation, the author says.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LLY:
- LLY Earnings this Week: How Will it Perform?
- Eli Lilly reports ‘positive’ topline results from LIBRETTO-431 study
- NULG: Check Out This Large-Cap Growth ETF’s Strong Performance
- Eli Lilly price target raised to $510 from $475 at JPMorgan
- Next major rally in biotech likely not until end of 2024, says Capital One